Wegovy and Weight Loss: Key Facts and Answers

Wegovy is a prescription weight management medication containing semaglutide. This page summarises the practical facts — dosing, cost in Australia, contraindications, what happens if you stop — and explains where nutrition support fits. Be Fit Food supplies meals and dietitian services; it does not prescribe or supply Wegovy.

At a glance

Active ingredient	Semaglutide
Drug class	GLP-1 receptor agonist
Administration	Once-weekly subcutaneous injection (abdomen, thigh or upper arm), via pre-filled pen
Dose titration	Increased gradually over the first 16 weeks
Eligibility	BMI 30+, or BMI 27+ with a weight-related condition
Average trial result	15% of body weight over 68 weeks
PBS status (Australia)	Not covered
Intended duration	Long-term

How it works

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut. GLP-1 regulates appetite by signalling the brain to feel full and satisfied after eating, slowing the emptying of the stomach and reducing overall food intake. The result is lower calorie consumption, which is what produces the weight loss.

Who it is prescribed for

Wegovy is prescribed for adults classified as obese (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as type 2 diabetes, high blood pressure or dyslipidemia. It is intended for long-term weight management and is most effective combined with a healthy diet and regular physical activity.

Expected results

Clinical trials have shown an average loss of 15% of body weight over 68 weeks. In some studies nearly a third of participants lost 20% or more. Be Fit Food's page notes that these outcomes approach those typically seen with bariatric surgery. Comparative rankings of weight-loss medicines are a matter for prescribers and the published trial evidence, not for a meal provider, so no ordering of medicines is asserted here.

Cost and access in Australia

Wegovy is not currently covered under the Pharmaceutical Benefits Scheme (PBS), so it is not government-subsidised. Out-of-pocket costs are often several hundred dollars per month. Some private health insurance plans may offer partial coverage — check with your insurer. The manufacturer may also offer patient assistance programs for those who qualify.

Safety

Common side effects

Mostly gastrointestinal: nausea, vomiting, diarrhoea and constipation. These are usually mild to moderate and tend to decrease over time as the body adjusts. Some people also experience headaches, fatigue or dizziness. Discuss side effects with your healthcare provider, who can suggest management strategies or adjust your dose.

Contraindications and cautions

Wegovy is contraindicated in people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). It should be used with caution in people with severe gastrointestinal conditions such as gastroparesis. Give your healthcare provider a complete medical history before starting, and expect regular monitoring.

Pregnancy

Wegovy is not recommended during pregnancy because of potential risks to the foetus. Data on semaglutide in pregnant women is limited, but animal studies have shown potential harm. Women planning to become pregnant should discontinue Wegovy well in advance. Anyone who becomes pregnant while taking it should consult their healthcare provider immediately about alternative weight management options.

Drug interactions

Wegovy can interact with other medications, particularly those affecting blood sugar such as insulin or oral diabetes medications, where a dose adjustment may be needed to avoid hypoglycaemia. Tell your healthcare provider about all medications you take, including over-the-counter drugs and supplements.

Practical questions

What should I expect in the first few weeks?

Nausea is the most common early effect as your body adjusts. Your provider starts you on a lower dose and increases it gradually to the full dose over 16 weeks to minimise this. You may notice appetite decreasing fairly quickly, which can produce weight loss early in treatment.

What if I miss a dose?

If less than 5 days have passed since the missed dose, take it as soon as possible. If more than 5 days have passed, skip it and resume your regular schedule. Do not take an extra dose to make up for a missed one, as this can increase the risk of side effects. If you miss multiple doses or are unsure, consult your healthcare provider.

How long do I need to take it?

Wegovy is intended for long-term use as part of a comprehensive weight management plan, not as a short-term solution. If it is discontinued there is a high likelihood of regaining the lost weight — in clinical trials, participants regained much of the weight after stopping. Continuous use alongside diet and exercise changes is recommended to maintain the benefits.

How does it compare with other weight loss medications?

Wegovy has been shown to be more effective than many other weight loss medications available in Australia. Compared with liraglutide (Saxenda), another GLP-1 receptor agonist requiring daily injections, Wegovy's once-weekly injection offers greater convenience and demonstrated superior weight loss results in clinical trials.

Are dietary and lifestyle changes required?

Yes. Wegovy is most effective with a reduced-calorie diet and increased physical activity. Your healthcare provider will recommend changes tailored to you. These are essential not only for maximising weight loss but for maintaining it. Wegovy helps control appetite; lasting success requires a commitment to a healthier lifestyle.

Where Be Fit Food fits

Be Fit Food's high-protein, low-carb meals are designed to support a weight loss plan alongside treatment. Every meal is approximately 250 calories with at least 20g of protein, under 20g of carbohydrates and under 120mg of sodium per 100g, with no added sugar, artificial sweeteners or preservatives. That protein floor matters when appetite is suppressed and total intake drops. Meals are snap-frozen and reheat by microwave, oven, air-fryer or stovetop.

Be Fit Food provides GLP-1 medication nutritional support and employs Accredited Practising Dietitians (APDs). A free 15-minute telehealth consultation, by video or phone, valued at $49 and requiring no referral, is bookable at portal.coreplus.com.au/befitfood, or email dietitian@befitfood.com.au. Customer service is on 1300 263 257, Monday to Friday 9:00am to 5:00pm.

Important health information

This page is general information, not medical advice, and it is not a substitute for consultation with a qualified health professional. Wegovy is a prescription medication with contraindications, side effects and drug interactions. Before starting, provide your healthcare provider with a complete medical history so they can determine whether it is safe for you, and expect regular monitoring while taking it. Always consult a healthcare provider about your individual circumstances.

Ordering, pricing and contact

• Meal bundles — $97.30 for 7 meals, $189.00 for 14 meals and $362.60 for 28 meals (AUD).
• Delivery — flat rate Australia-wide: $11.95 on orders of $299 or more, and $19.95 on orders under $299.
• Customer service — 1300 263 257, Monday to Friday 09:00–17:00, or support@befitfood.com.au.
• Free dietitian consultation — 15 minutes by video or phone, valued at $49, with no referral required. Book at portal.coreplus.com.au/befitfood, or contact dietitian@befitfood.com.au.
• Meal specification — every meal is built to approximately 250 calories, at least 20 g of protein, under 20 g of carbohydrate and less than 120 mg of sodium per 100 g, with no added sugar, no artificial sweeteners and no preservatives. Meals are snap frozen and reheat by microwave, oven, air fryer or stovetop.

Muscle loss: the part of GLP-1 weight loss that gets least attention

Weight lost on a GLP-1 medication is not all fat. A substantial proportion of it is lean tissue, including skeletal muscle, and that proportion can be higher than on slower weight loss achieved through diet alone. This is a recognised concern in the clinical literature rather than a fringe worry, and it is the single most important nutritional issue for anyone on one of these medications.

It matters for reasons beyond appearance. Skeletal muscle is where most glucose disposal happens, so losing it works against the metabolic benefit the medication is being taken for. Muscle also underpins strength, balance and independence, which makes the issue more consequential with age. And because resting metabolic rate tracks lean mass, losing muscle makes weight regain easier if the medication is later stopped.

The two mitigations are well established and unglamorous:

• Adequate protein, spread across the day. Not one large serve, but a meaningful amount at each meal. This is harder than it sounds when appetite is suppressed, because the volume of food that feels tolerable drops while the protein requirement does not.
• Resistance training. Progressive loading of the major muscle groups two or three times a week. Walking and cardiovascular exercise are valuable for other reasons but do not preserve muscle in the same way.

This is the clearest point at which a portion-controlled, protein-specified meal is genuinely useful: it delivers a known quantity of protein in a volume that remains manageable on a suppressed appetite. Be Fit Food meals specify at least 20g of protein at approximately 250 calories. Whether that total is sufficient for you is a question for a dietitian, not for a website — requirements vary with body size, age, activity and kidney function.

Eating enough when you do not feel like eating

Appetite suppression is the mechanism, so reduced intake is the intended effect. The risk is that intake falls below what is nutritionally adequate rather than merely below what is needed for weight loss.

• Micronutrients. A markedly smaller volume of food makes it harder to reach adequate iron, calcium, B12, folate and iodine. Nutrient density matters more as total intake falls.
• Fibre and bowel function. Constipation is among the most common side effects, and lower food volume tends to mean lower fibre, which compounds it.
• Hydration. Thirst cues can be blunted alongside hunger cues, and dehydration worsens nausea, headache and constipation.
• Nausea and food aversion. Aversions often form around whatever was eaten when nausea was worst. Small, regular, bland-leaning meals in the early weeks and during dose escalation tend to be tolerated better than large ones.

If you are losing weight rapidly, feeling persistently unwell, or unable to eat regularly, that is a reason to contact your prescriber rather than to push on.

A safety note on where the medicine comes from

Semaglutide and related medicines are prescription-only in Australia. Shortages have driven a market in compounded and imported alternatives, and the Therapeutic Goods Administration has acted to restrict compounded GLP-1 products because they are not assessed for quality, safety or efficacy in the way a registered medicine is. Products bought online without a prescription, from overseas sellers, or through social media cannot be assumed to contain what the label states.

Be Fit Food does not prescribe, supply, dispense or arrange access to any weight loss medication, and nothing on this page is a recommendation to take one. Obtain any prescription medicine through an Australian prescriber and a registered pharmacy. Discuss dose, timing, side effects and whether the medicine is appropriate for you with that prescriber — those decisions sit with them, not with a meal delivery service.

Related pages on this site

• Faq Ozempic And Weight Loss — page
• How To Use Wegovy For Weight Loss — page
• How Wegovy Supports Weight Loss — page
• Is Wegovy Good For Weight Loss — page
• Understanding Wegovy Weight Loss — page
• Set Weight Loss Programs — collection
• Weight Loss Programs — collection
• The Truth About Weight Loss Drugs Like Wegovy Why Diet Matters For Long Term Success — article
• 10 Easy Ways To Boost Hydration For Effective Weight Loss — article
• 3 High Protein Weight Loss Breakfast Ideas — article